TONGHUA GOLDEN-HORSE(000766)2024-04-18 11:37Financial Performance - The company's operating revenue for 2023 was ¥1,473,345,301.05, a slight increase of 0.18% compared to ¥1,470,748,775.14 in 2022[11]. - Net profit attributable to shareholders for 2023 reached ¥43,933,703.90, representing a significant increase of 45.71% from ¥30,151,348.90 in 2022[11]. - The net profit after deducting non-recurring gains and losses was ¥29,424,093.57, up 45.35% from ¥20,243,471.47 in the previous year[11]. - Basic and diluted earnings per share increased by 66.67% to ¥0.05 from ¥0.03 in 2022[11]. - The company achieved operating revenue of ¥1,473,345,301.05, representing a year-on-year growth of 0.18%[23]. - The net profit attributable to shareholders was ¥43,933,703.90, reflecting a significant increase of 45.71% year-on-year[23]. - The net profit attributable to shareholders after deducting non-operating gains and losses was ¥29,424,093.57, up by 45.35% compared to the previous year[23]. - The company reported a total of ¥14,509,610.33 in non-recurring gains for 2023, compared to ¥9,907,877.43 in 2022[15]. Shareholder Information - The company plans not to distribute cash dividends, nor issue bonus shares, or increase capital from reserves[2]. - The largest shareholder has changed to Yu Lanjun after a series of court rulings related to financial disputes involving Beijing Jinchang Investment Management Co., Ltd.[9]. - The company experienced a significant change in shareholder structure, with the number of common shareholders increasing from 59,452 to 75,318 during the reporting period[130]. - The largest shareholder, Yu Lanjun, holds 19.66% of the shares, totaling 190,000,000 shares, which are currently pledged[131]. - The company has a total of 8 major shareholders holding more than 5% of the shares, with no related party transactions among them[131]. Research and Development - The company is actively involved in R&D for both innovative and generic drugs, with a focus on improving quality standards and optimizing production processes[21]. - The company holds a total of 38 invention patents, 78 utility model patents, and 2 design patents, with 13 invention patents currently under review[24]. - The company has fully controlled a research company focused on developing treatments for mild to moderate Alzheimer's disease, enhancing its R&D capabilities[24]. - Research and development expenses decreased by 29.41% to ¥45,820,415.81 in 2023 from ¥64,908,683.10 in 2022[34]. - The number of R&D personnel increased by 4.09% to 331 in 2023 from 318 in 2022, with a proportion of 21.00% of total employees[37]. Market Strategy - The company is focusing on the development of traditional Chinese medicine and has aligned its strategies with national policies to enhance its market position[17]. - The sales strategy includes direct sales and agency models, with a focus on academic promotion to enhance product recognition among healthcare professionals[21]. - The company aims to maintain stable growth despite competitive pressures and uncertainties in the pharmaceutical industry, guided by a strategy of "rectification, reform, and development"[21]. - The company plans to improve marketing capabilities and optimize sales models to increase market share, focusing on key product performance indicators[56]. Environmental Compliance - The company maintained compliance with various environmental protection laws and standards during its operations[96]. - The company has a valid wastewater discharge permit effective until November 20, 2027[97]. - The average COD concentration in wastewater discharge was 16.37 mg/L, with a total COD discharge of 4.09 tons[98]. - The company reported a total nitrogen oxide emission of 25 tons per year, with no exceedances of discharge standards[98]. - The company has implemented measures to ensure compliance with environmental standards, including specific pollutant discharge limits[96]. Corporate Governance - The company has established an independent financial accounting system and management practices, operating as a separate taxpayer without shared bank accounts with the controlling shareholder[64]. - The company has engaged in multiple investor communications regarding new drug progress and operational conditions throughout 2023[58]. - The company held 4 shareholder meetings during the reporting period, ensuring compliance with legal requirements and protecting the rights of all shareholders, especially minority shareholders[62]. - The company has not reported any penalties from regulatory authorities for its directors and supervisors in the past three years[76]. Financial Position - Total assets at the end of 2023 were ¥4,519,244,365.23, down 3.54% from ¥4,685,114,987.39 at the end of 2022[11]. - Net assets attributable to shareholders decreased by 0.82% to ¥2,317,662,919.56 from ¥2,336,859,413.77 in 2022[11]. - The company's cash flow from operating activities decreased by 43.09% to ¥112,779,071.13 from ¥198,163,857.90 in 2022[11]. - The total liabilities as of December 31, 2023, amounted to CNY 2,201,117,186.94, down from CNY 2,316,613,744.76 in the previous year, a decrease of about 4.97%[150]. Future Outlook - In 2024, the company aims to enhance innovation, market development, and research support to create greater value for customers, employees, and society[55]. - The company is committed to sustainability, with plans to invest 50 million yuan in eco-friendly practices over the next three years[72]. - The company plans to continue expanding its market presence and developing new products and technologies in the upcoming fiscal year[76].